Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
BACKGROUND: The findings from therapeutic trials in HIV infection with surrogate endpoints based on laboratory markers are only partially relevant for clinical decisions on treatment. Although the collection of clinical follow-up data from such a trial would be relatively straightforward, this rarely occurs. An important reason for this may be the perception that such data have little value because the number of participants remaining on their original allocated therapy has usually fallen su...Expand abstract
- Publisher copy:
- Copyright date: